PD 184352
Chemical Name: 2-[(2-Chloro-4-iodophenyl)amino]-N-cyclopropylmethoxy)-3,4-difluorobenzamide
Biological Activity
PD 184352 is a selective MEK inhibitor (Ki = 300 nM in vitro). Suppresses FGF-mediated angiogenesis in vivo and decreases VEGF expression. Enhances the therapeutic efficacy of taxol (Cat. No. 1097) in vivo. Orally active.Technical Data
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Additional Information
Background References
-
Phosphoinositide 3-kinase p110? negatively regulates thrombopoietin-mediated platelet activation and thrombus formation
TA Blair, SF Moore, TG Walsh, JL Hutchinson, TN Durrant, KE Anderson, AW Poole, I Hers
Cell. Signal., 2018;0(0):. -
CI-1040 (PD184252), a targeted signal transduction inhibitor of MEK (MAPKK).
Allen et al.
Semin.Oncol., 2003;30:105 -
BRAF mutation predicts sensitivity to MEK inhibition.
Solit et al.
Nature, 2006;439:358 -
Enhancement of the therapeutic efficacy of Tax. by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
McDaid et al.
Cancer Res., 2005;65:2854
Product Datasheets
Citations for PD 184352
The citations listed below are publications that use Tocris products. Selected citations for PD 184352 include:
4 Citations: Showing 1 - 4
-
Activation of protein synthesis in mouse uterine epithelial cells by OE-17β is mediated by a PKC-ERK1/2-mTOR signaling pathway.
Authors: Wang Et al.
BMC Res Notes 2015;112:E1382
-
Central role for protein kinase C in oxyt. and epidermal growth factor stimulated cyclooxygenase 2 expression in human myometrial cells.
Authors: Wouters Et al.
Genes Cancer 2014;7:357
-
miR-155 induced transcriptome changes in the MCF-7 breast cancer cell line leads to enhanced mitogen activated protein kinase signaling.
Authors: Martin Et al.
J Exp Bot 2014;5:353
-
Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.
Authors: W Michael Et al.
Mol Cancer Ther 2013;12:2213-25
FAQs
No product specific FAQs exist for this product, however you may
View all Small Molecule FAQsReviews for PD 184352
There are currently no reviews for this product. Be the first to review PD 184352 and earn rewards!
Have you used PD 184352?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
